SCHEMBL19259894

SCHEMBL19259894

CCCCC(CC)COC(=O)CCSc1cc(C(=O)O)cc(-c2ccccc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.48
TSHR P16473 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
ATM Q13315 1/20 0.48
ALDH1A1 P00352 7/20 0.46
CA2 P00918 1/20 0.46
MAPK1 P28482 4/20 0.46
LMNA P02545 3/20 0.46
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42
PRSS3 P35030 1/20 0.42
HSD17B10 Q99714 1/20 0.40
PTGES O14684 1/20 0.38
ALOX5 P09917 1/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
RECQL P46063 1/20 0.38
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19274638 0.91 ALDH1A1 (0.47) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL19259938 0.91 CYP3A4 (0.45) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL19259597 0.89 CYP3A4 (0.49) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL29970991 0.89 ALDH1A1 (0.44) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL28643938 0.89 CYP3A4 (0.51) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL19259738 0.88 ALDH1A1 (0.49) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL19259587 0.88 CYP3A4 (0.48) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL19259973 0.87 CYP3A4 (0.47) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL19259872 0.87 CYP3A4 (0.51) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL19260185 0.86 CYP3A4 (0.46) CYP3A4TSHRTDP1ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416956-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER The Institute of Cancer Research : The Royal Cancer Hospital (GB) 2018-12-26 EP disclosed
WO-2017141049-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2017-08-24 WO disclosed